Alzheimer’s Blood Test Brings Early Detection to Primary Care

Roche’s Elecsys pTau181 test may help family doctors rule out Alzheimer’s-related brain changes before specialist referral

The FDA has cleared Roche’s Elecsys pTau181 as the first blood-based biomarker test for Alzheimer’s usable in primary care, showing a 97.9% negative predictive value in ruling out amyloid pathology in older adults with cognitive decline.

Study Details:

The Elecsys pTau181 test measures phosphorylated tau 181 (p-tau181) in plasma, a protein fragment linked…